CA2439468A1 - Nouvelles formes cristallines de lamotrigine et leurs procedes de preparation - Google Patents

Nouvelles formes cristallines de lamotrigine et leurs procedes de preparation Download PDF

Info

Publication number
CA2439468A1
CA2439468A1 CA002439468A CA2439468A CA2439468A1 CA 2439468 A1 CA2439468 A1 CA 2439468A1 CA 002439468 A CA002439468 A CA 002439468A CA 2439468 A CA2439468 A CA 2439468A CA 2439468 A1 CA2439468 A1 CA 2439468A1
Authority
CA
Canada
Prior art keywords
lamotrigine
crystalline
diffraction pattern
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002439468A
Other languages
English (en)
Inventor
Nissim Garti
Yana Berkovich
Ben-Zion Dolitzky
Judith Aronhime
Claude Singer
Anita Lieberman
Neomi Gershon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2439468A1 publication Critical patent/CA2439468A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

La présente invention concerne la lamotrigine, agent anti-épileptique utile ainsi que des nouvelles formes cristallines de la lamotrigine qui renferment des molécules du solvant en proportions stoechiométriques. L'invention concerne également de nouveaux procédés d'obtention de formes cristallines de lamotrigine.
CA002439468A 2001-02-27 2002-02-27 Nouvelles formes cristallines de lamotrigine et leurs procedes de preparation Abandoned CA2439468A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27168801P 2001-02-27 2001-02-27
US60/271,688 2001-02-27
PCT/US2002/006160 WO2002068398A1 (fr) 2001-02-27 2002-02-27 Nouvelles formes cristallines de lamotrigine et leurs procedes de preparation

Publications (1)

Publication Number Publication Date
CA2439468A1 true CA2439468A1 (fr) 2002-09-06

Family

ID=23036634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002439468A Abandoned CA2439468A1 (fr) 2001-02-27 2002-02-27 Nouvelles formes cristallines de lamotrigine et leurs procedes de preparation

Country Status (6)

Country Link
US (3) US6861426B2 (fr)
EP (1) EP1390355A4 (fr)
JP (1) JP2004526714A (fr)
CA (1) CA2439468A1 (fr)
IL (1) IL157608A0 (fr)
WO (1) WO2002068398A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439468A1 (fr) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines de lamotrigine et leurs procedes de preparation
EP1496864B1 (fr) * 2002-04-23 2007-03-21 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique contenant des particules de lamotrigine de morphologie definie
US7521553B2 (en) 2003-03-17 2009-04-21 Hetero Drugs Limited Crystalline forms of lamotrigine
AU2003230193A1 (en) 2003-03-27 2004-10-18 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
WO2009061513A1 (fr) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Formes cristallines de lamotrigine
CN114948868B (zh) * 2021-04-16 2023-04-14 上海奥科达医药科技股份有限公司 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物
CN115068422B (zh) * 2022-08-19 2022-11-29 上海奥科达生物医药科技有限公司 一种拉莫三嗪湿混悬剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059987B1 (fr) 1979-06-01 1985-08-14 The Wellcome Foundation Limited Alpha-cyano-alpha-((N-guanidino)-imino)toluènes
JPS5625170A (en) * 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
ES8604019A1 (es) 1985-04-15 1986-01-16 Nippon Shinyaku Co Ltd Un procedimiento para preparar polvo fino de 2,5-dicloroben-zoguanamina y sus sales
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US5643591A (en) 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9426448D0 (en) 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
US6525185B1 (en) 1998-05-07 2003-02-25 Affymetrix, Inc. Polymorphisms associated with hypertension
CA2334937C (fr) * 1998-12-14 2004-09-21 Torrent Pharmaceuticals Ltd. Procede et appareil ameliore de preparation de 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
IL148801A0 (en) 1999-09-24 2002-09-12 Janssen Pharmaceutica Nv Antiviral compositions
US6639072B1 (en) 2000-01-03 2003-10-28 Rpg Life Sciences Limited Process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
AU2001266689A1 (en) 2000-06-08 2001-12-17 Merck And Co., Inc. 4-benzyl-2-hydroxy-1,4-oxazin-3-one and polymorphic forms thereof
CA2439468A1 (fr) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines de lamotrigine et leurs procedes de preparation
US6492379B1 (en) 2002-02-21 2002-12-10 Super Gen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
US20040247689A1 (en) 2003-03-26 2004-12-09 Guy Samburski Process for preparing a pharmaceutical active ingredient with high specific surface area

Also Published As

Publication number Publication date
US7390807B2 (en) 2008-06-24
IL157608A0 (en) 2004-03-28
US20050171107A1 (en) 2005-08-04
EP1390355A2 (fr) 2004-02-25
US20080139808A1 (en) 2008-06-12
JP2004526714A (ja) 2004-09-02
US6861426B2 (en) 2005-03-01
EP1390355A4 (fr) 2005-02-23
US20030018030A1 (en) 2003-01-23
WO2002068398A1 (fr) 2002-09-06
WO2002068398A9 (fr) 2002-11-21

Similar Documents

Publication Publication Date Title
US7390807B2 (en) Crystal forms of lamotrigine and processes for their preparations
US20220144825A1 (en) Solid state forms of ripretinib
EP1511739B1 (fr) Formes polymorphes de valsartan
US20210317085A1 (en) Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
US20230339962A1 (en) Solid state forms of sep-363856 and process for preparation thereof
US20040235904A1 (en) Crystalline and amorphous solids of pantoprazole and processes for their preparation
EP4352056A1 (fr) Formes à l'état solide de lanifibranor et leur procédé de préparation
WO2022177927A1 (fr) Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
US20040192700A1 (en) Novel crystalline forms of gatifloxacin
IL298629A (en) Methods and dosage forms for osmotic administration of pharmaceutical preparations containing deuterobenzene
WO2021154987A1 (fr) Formes à l'état solide de mitapivat et leur procédé de préparation
US20240173304A1 (en) Solid state forms of tideglusib and process for preparation thereof
WO2021133811A1 (fr) Formes solides de cenicriviroc et leur procédé de préparation
US20220380288A1 (en) Solid state forms of fezagepras and process for preparation thereof
WO2022060945A1 (fr) Formes à l'état solide de gefapixant et leur procédé de préparation
US20080027128A1 (en) Duloxetine HCL polymorphs
WO2023199258A1 (fr) Formes à l'état solide de mavacamten et leur procédé de préparation
EP4387960A1 (fr) Polymorphes de ponésimod
WO2024095127A1 (fr) Formes à l'état solide de tivozanib et leur procédé de préparation
WO2024089582A1 (fr) Formes à l'état solide de sels de cilofexor
AU2003268213A1 (en) Crystalline solid famciclovir forms i, ii, iii and preparation thereof
EP4229057A1 (fr) Formes à l'état solide de lorécivivint
WO2020154581A1 (fr) Formes à l'état solide d'un co-cristal de fédovapagon-acide salicylique
WO2007016209A2 (fr) Sel de sodium d'acide 1,2-benzisoxazole-3-methane-sulfonique pur et procede de purification

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued